CHU Amiens
Amiens, 80480, France
Location status: Recruiting
NCT Number: NCT04348838
Hepatocellular carcinoma (HCC) occurs in 90% of cirrhosis primary liver cancers. In France, 8,500 new cases of HCC occur each year, and about 8,000 deaths per year are related to this cancer. The 5-year survival rate is 10%, one of the lowest survival rates of all cancer types. HCC raises a number of major challenges: HCC is discovered at a curable stage in only 25% of cases, reflecting the marked delay in the diagnosis of early stages. The state of knowledge about HCC is well behind that of other cancers (no biomarker, complex carcinogenesis, influence of the aetiology, poorly valorised data, etc.). Rapid technological progress requires large-scale studies to evaluate new diagnostic and therapeutic modalities.
The CHIEF project constitutes a common basis knowledge for research project using prospectively collected data in patients with HCC, regardless of the cause and stage of the cancer.
This project is a Multicentre longitudinal observational study of patients with HCC with prospective data collection on inclusion and patient follow-up. Constitution of a biological resources collection. 5,000 patients will be included over 2 years with a follow-up of patients of 5 years.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Amiens, 80480, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: from day 1 of inclusion, up to 5 years
Variation of progression free survival (PFS) in intent to treat after liver transplantation
Time frame: from day 1 of inclusion, up to 5 years
Variation of time until failure of the strategy after hepatic resection and percutaneous destruction
Time frame: from day 1 of inclusion, up to 5 years
Variation of overall survival time (OS) after chemoembolization
Time frame: from day 1 of inclusion, up to 5 years
Variation of overall survival time (OS) after radioembolization
Time frame: from day 1 of inclusion, up to 5 years
Variation of overall survival time (OS) after pharmaceutical treatment
Time frame: from day 1 of inclusion, up to 5 years
Variation of adverse event rate of HCC treatments in clinical practice
Time frame: from day 1 of inclusion, up to 5 years
Variation of serious adverse event rate of HCC treatments in clinical practice
Contact information is provided by the study sponsor or research team.
Gérard DUCOURNAU, Ing
CONTACT
Olivier Ganry, Pr
CONTACT
Centre Hospitalier Universitaire, Amiens
Other
Acronym: CHIEF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03452774
Adenocarcinoma, Adnexal Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04258813
Adenocarcinoma, Adnexal Diseases
Durham, North Carolina, United States
View Trial DetailsNCT05179824
Adnexal Diseases, Bile Duct Diseases
Dallas, Texas, United States
View Trial DetailsNCT05041335
Cancer, Cancer of Esophagus
Tampa, Florida, United States
View Trial Details